ICON's fastest-growing therapeutic area and testament to our success in conducting oncology clinical trials.

Oncology Clinical Trials

Oncology is currently ICON's fastest-growing therapeutic area and a testament to our success in conducting oncology clinical trials. In the past 5 years alone, ICON has conducted over 950 oncology studies, assessing over 148,000 patients at nearly 27,500 sites worldwide.

ICON’s Oncology Solution expedites every aspect of a cancer drug trial. It combines global experience in all Phases of oncology drug development with expertise in tumor imaging, laboratory (including PK/PD and Biomarkers) IVRS, central data management , electronic data capture and regulatory oncology issues.

Our clinical trial experience includes the following oncology indications:

  • Bladder
  • Brain
  • Breast
  • Gastrointestinal, Colorectal
  • Cervical
  • Head & Neck
  • Hepatic
  • Hematological Malignancies
  • Leukemia (all types)
  • Lymphoma and Non Hodgkin
  • Melanoma
  • Thyroid
  • Solid Tumors

Oncology Scientific Council and Oncology Centre of Excellence

The in-depth therapeutic and operational knowledge of ICON’s Scientific Council and Oncology Centre of Excellence spans the entire drug development process. The Scientific Council provides scientific oversight and direction while the Centre of Excellence focuses on operational and training support of ICON’s project teams executing oncology studies.  Senior members of these groups have extensive haematology and oncology drug development and have worked on a wide variety of oncology programs and drug classes, including:

  • Clinical Development Methodology
  • Anti-angiogenics
  • TKI
  • Anti-metastatics
  • Cytostatics
  • Cytotoxics
  • Hormonal treatments
  • Gene therapies 
  •  Hemopoietic growth factors
  • Imaging agents
  • Interferon
  • Interleukin
  • Monoclonal antibodies
  • New delivery systems
  • Retinoids
  • Vaccines
  • Tumor biomarkers

The scope of responsibilities for ICON’s Oncology Scientific Council and Oncology Centre of Excellence members includes:

  • Global project feasibility
  • Participation in country and site selection
  • Protocol development, review and evaluation
  • Clinical trial planning and execution
  • Therapeutic experience and training
  • Consulting, medical monitoring and advisory board representation 
  • Interpretation of the clinical data
  • Completion of the clinical study report
  • Investigator/sponsor relationships

Investigative Sites

Our global investigator database includes thousands of oncology investigative sites worldwide. As such, ICON has close working relationships and consulting agreements with physicians at most of the major tertiary and academic cancer treatment centers as well as cooperative groups and consortiums. These extensive and well-established relationships provide ICON with the ability to obtain information quickly and concisely regarding development issues in oncology and effective recruitment strategies.